Table 2.

Serum Levels (ng/ml) of the Antipsychotic Drugs HAL and CLZ (and Their Major Metabolites Reduced HAL and Desmethylclozapine, Respectively) and of the Antidepressant Drug FLX and Its Metabolite Norfluoxetine After Subchronic (5 d) and Chronic (15 d) Treatment

	HAL	Reduced HAL	CLZ	Desmethylclozapine	FLX	Norfluoxetine
5-d treatment	110.4 ± 24.3	ND	25.6 ± 7.0	73.7 ± 10.1	576.3 ± 59.2	823.8 ± 67.6
15-d treatment	110.3 ± 33.4	ND	33.8 ± 5.2	147.9 ± 21.3*	1035.1 ± 72.6#	1126.9 ± 58.4§

Note: HAL, haloperidol; CLZ, clozapine; FLX, fluoxetine; ND, not detected. The antipsychotic and antidepressant drugs were administered to male and female C57BL/6 mice via home cage drinking bottles at doses of 3 mg/kg/day (HAL), 15 mg/kg/day (CLZ), and 20 mg/kg/day (FLX). The drug regime was conducted during the periadolescent stage of development, ie, from postnatal day 35 onward. Preliminary statistical analyses indicated that there were no significant differences between the serum drug levels in male and female mice. The antipsychotic and antidepressant drugs and their major metabolites were no longer detectable in the serum following a washout period of 3 wk (data not shown). *P < .01 between desmethylclozapine levels after 5- and 15-d treatment, ^#P < .01 between FLX levels after 5- and 15-d treatment, and ^§P < .001 between norfluoxetine levels after 5- and 15-d treatment based on independent Student t tests. N(HAL) = 10 (4 ♂, 6 ♀), N(CLZ) = 10 (5 ♂, 5 ♀), and N(FLX) = 10 (6 ♂, 4 ♀). The serum levels of reduced HAL were below detection limit (ND). All values are means ± standard error of the mean.